Loading patent…
AssigneeLudwig Institute for Cancer Research
InventorsJean-Christophe Renauld, Jamila Louahed, Roy Levitt, Nicholas Nicolaides, Qu Dong
Estimating the term…
A new gene in the G-coupled protein receptor family is discribed that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and certain lymphomas or leukemias. A method for recombinantly producing the polypeptide encoded by the gene is disclosed. A method for identification and use of agonist and antagonists of GCR9 to treat atopic allergy, asthma-related disorders and certain lymphomas or leukemias is also included. A method for diagnosing susceptibility to, and assessing treatment of atopic allergy, asthma-related disorders and certain lymphomas or leukemias by measuring the level of GCR9 in biological samples using antibody specific for the GCR9 polypeptide or nucleic acid probes specific for GCR9 nucleic acids is also disclosed.
A purified and isolated DNA molecule having a nucleotide sequence encoding murine GCR9 or functionally equivalent fragments thereof.
A purified and isolated DNA molecule having a nucleotide sequence encoding human GCR9 or functionally equivalent fragments thereof.
A chemically synthesized DNA molecule having a nucleotide sequence encoding human GCR9 or functionally equivalent fragments thereof.
A chemically synthesized DNA molecule having a nucleotide sequence encoding murine GCR9 or functionally equivalent fragments thereof.
A purified and isolated RNA molecule having a nucleotide sequence encoding human GCR9 or functionally equivalent fragments thereof.
A purified and isolated RNA molecule having a nucleotide sequence encoding murine GCR9 or functionally equivalent fragments thereof.
A purified and isolated polypeptide having an amino acid sequence comprising human GCR9 or functionally equivalent fragments thereof.
A purified and isolated polypeptide having an amino acid sequence comprising murine GCR9 or functionally equivalent fragments thereof.
A method of alleviating asthma-related disorders by administering to patients in need of such treatment an equivalent amount of a compound to down-regulate the function of human GCR9.
A method according to claim 12 wherein the compound comprises the antibody of claims 30 or 31.
A method for detecting or diagnosing susceptibility to asthma-related disorders and certain lymphomas and leukemias associated with elevated levels of GCR9 polypeptide in a human subject comprising the steps of:
A method for monitoring a therapeutic treatment of asthma-related disorders or certain lymphomas or leukemias associated with elevated levels of GCR9 polypeptide in a human subject comprising;
A method of treating a tumor by administering to patients in need of such treatment an effective amount of a compound to down-regulate the function of human GCR9.
A method according to claim 19 wherein the compound comprises the antibody of claims 30 or 31.
A method for identifying antagonists of GCR9 comprising the steps of:
A method for identifying antagonists of GCR9 comprising the steps of:
A method for identifying agonists of GCR9 comprising the steps of:
Antisense DNA comprising the antisense sequence of human GCR9 or active fragments thereof.
A method according to claim 12 wherein the compound comprises the antisense DNA of claim 38.
An isolated nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having a sequence complementary to either SEQ ID NO:1 or SEQ ID NO:3.
Dependencies are inferred from the claim text.